MDACC Study No:2012-0598 ( NCT No: NCT01904682)
Title:Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 Myelodysplastic Syndrome Patients Based on International Prognostic Scoring System
Principal Investigator:Elias Jabbour
Treatment Agent:RIGOSERTIB SODIUM (ON 01910.Na)
Study Status:Closed
Study Description:The goal of Part 1 of this clinical research study was to find the highest
tolerable dose of rigosertib that can be given to patients with MDS. Part 1 is
now complete.

The goal of Part 2 of this study is to learn if rigosertib can help to control
MDS. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:RIGOSERTIB SODIUM (ON 01910.Na)
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Onconova Therapeutics Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Elias Jabbour
For Clinical Trial Enrollment:713-792-4764
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults